Ondansetron Fresenius Kabi (Ondansetron Hydrochloride Dihydrate)

Ondansetron Hydrochloride Dihydrate, the active ingredient in Ondansetron Fresenius Kabi, is a 5-HT3 receptor antagonist presented as a sterile injectable solution for intravenous use. It helps prevent nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative recovery in adult and pediatric patients.

GNH USA supplies Ondansetron Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron Fresenius Kabi is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting related to several clinical pathways.

- Chemotherapy‑induced nausea and vomiting: Reduces the frequency and severity of acute and delayed episodes. - Radiotherapy‑induced nausea and vomiting: Helps control nausea during and after radiation treatment. - Post‑operative nausea and vomiting (PONV): Decreases the incidence of nausea and vomiting after surgical procedures. - Hyper‑emesis gravidarum (off‑label): May be used when conventional anti‑emetics are ineffective, under specialist supervision.

Adverse reactions to ondansetron are generally dose‑related and vary from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel habit changes. - Diarrhoea: transient loose stools. - Fatigue: feeling of tiredness. - Dizziness: light‑headed sensation. - Injection site pain: mild discomfort at the IV site.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation, especially with rapid IV administration. - Severe hypersensitivity: rash, itching, or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic enzyme elevation: abnormal liver function tests. - Severe constipation or intestinal obstruction. - Neuroleptic malignant‑like reactions: rare, characterized by high fever and muscle rigidity.

When using Ondansetron Fresenius Kabi, clinicians should consider several safety aspects.

- Cardiac monitoring: patients with known QT prolongation or electrolyte disturbances should be monitored. - Electrolyte balance: correct hypokalaemia, hypomagnesaemia, or hypocalcaemia before administration. - Concomitant serotonergic drugs: assess risk of serotonin syndrome. - Pregnancy and lactation: use only if clearly needed. - Pediatric dosing: adjust dose according to weight and age guidelines. - Store at ambient temperature: keep in original packaging, protect from light and moisture.

Ondansetron may interact with several medicines, requiring attention to the interaction severity.

Major Interactions (Avoid): - Anti‑arrhythmic agents (e.g., amiodarone, quinidine): increase risk of QT prolongation. - Certain antipsychotics (e.g., haloperidol, ziprasidone): additive effect on cardiac repolarisation. - Serotonergic agents (e.g., tramadol, linezolid): heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise ondansetron plasma levels. - CYP2D6 substrates (e.g., metoprolol, codeine): potential alteration of their metabolism. - Oral contraceptives: possible reduction in efficacy, requiring counseling. - Proton pump inhibitors: may modestly affect absorption of oral formulations. - Diuretics: monitor electrolytes to avoid QT‑related complications.